Corporate Presentation

Christopher U Missling, PhD | President & CEO Nasdaq: AVXL | November 2020 Forward Looking Statement

This presentation contains forward-looking statements made within the meaning of the Private Securities Litigation Reform Act of 1995 by Anavex® Life Sciences Corp. and its representatives. These statements can be identified by introductory words such as “expects,” “plans,” “intends,” “believes,” “will,” “estimates,” “forecasts,” “projects,” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in reports filed by Anavex Life Sciences Corp. with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Anavex Life Sciences Corp. undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Anavex Life Sciences Corp. cannot be sure when or if it will be permitted by regulatory agencies to undertake clinical trials or to commence any particular phase of any clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Anavex Life Sciences Corp. will obtain regulatory approval for any “phase” of clinical trials. We also cannot be sure of the clinical outcome for efficacy or safety of our compounds. Potential investors should refer to the risk factors in our reports filed on Edgar.

2 Broad Pipeline Targeting Neurodegenerative and Neurodevelopmental Diseases with Significant Unmet Medical Need CANDIDATE PRECLINICAL PHASE 1 PHASE 2 PHASE 3

AD ANAVEX®2-73-AD-004 ANAVEX®2-73 ALZHEIMER’S DISEASE (Blarcamesine) PARKINSON’S DISEASE DEMENTIA ANAVEX®2-73-PDD-001

*RETT SYNDROME EXCELLENCE ANAVEX®2-73-RS-003

*RETT SYNDROME U.S. ANAVEX®2-73-RS-001 Fast Track, Rare Pediatric, Orphan Drug (U.S./EU) *RETT SYNDROME AVATAR ANAVEX®2-73-RS-002

*INFANTILE SPASMS FRAGILE X ANGELMAN’S

*FRONTOTEMPORAL DEMENTIA (FTD) ANAVEX®3-71-001 ANAVEX®3-71 (AF710B) ALZHEIMER’S DISEASE PARKINSON’S DISEASE • Differentiated clinical-stage CNS assets targeting significant and growing markets DEPRESSION ANAVEX®1-41 STROKE • Patent protection to 2030-2039, worldwide rights PARKINSON’S DISEASE for all product candidates ALZHEIMER’S DISEASE

VISCERAL PAIN ANAVEX®1066 ACUTE & NEUROPATHIC PAIN

* = Orphan Drug Designation by FDA 3 Targeting Large Market Opportunities with Significant Unmet Medical Need All U.S. Patient Numbers

1) Alzheimer’s Disease Facts and Figures. Alzheimers Dement 2018;14(3):367-429. 2) Marras C et al 2018. npj Parkinson's Disease volume 4, Article number: 21 3) Based on prevalence number on orphanet 4 Transformative Events for Anavex • Rett Syndrome Program Received Fast Track Designation and is Eligible for Pediatric Priority Review Voucher • Pursuing Large Markets with High Unmet Need by Applying Genetic Precision Medicine • Novel CNS Mechanism of Action Upstream of Neurodevelopment and Neurodegeneration • Compelling first Human Patient Data in Parkinson’s Disease Dementia, Rett Syndrome and Alzheimer’s Disease

• Sufficient Cash for >24 months To Achieve Key Milestones – Including non-dilutive Cash from Australian Government for Alzheimer’s Trial, and from Rettsyndrome.org for Rett Syndrome Trial Continued Significant Value-creating Events with Several Clinical Readouts in 2020/2021:

• Two Phase 2 Adult Rett Syndrome Trials (ClinicalTrials.gov Identifier: NCT03758924, NCT03941444)

• Phase 2/3 Pediatric Rett Syndrome Trial (ClinicalTrials.gov Identifier: NCT04304482)

• Phase 2b/3 Alzheimer’s Disease Trial (ClinicalTrials.gov Identifier: NCT03790709)

® • Phase 1 of ANAVEX 3-71 with focus on Frontotemporal Dementia (ClinicalTrials.gov Identifier: NCT04442945)

5 Catalysts to Drive Value The company has multiple near-term clinical milestones Full enrollment Phase 2 Parkinson’s disease dementia (PDD) Rett syndrome program received FDA Fast Track Designation and is eligible for FDA Pediatric Priority Review Voucher Initiate EXCELLENCE Phase 2/3 in pediatric Rett syndrome (RTT) Initiate Phase 1 ANAVEX®3-71 Full enrollment U.S. Phase 2 RTT Topline data Phase 2 PDD Topline data U.S. Phase 2 RTT – Q4 2020 Topline data AVATAR Phase 2 RTT – 1H 2021 Topline data Phase 1 ANAVEX®3-71 – 1H 2021

6 Clinical Trials – MoA and First Clinical Data: • Rett Syndrome (RTT) • Alzheimer’s Disease (AD) • Parkinson’s Disease Dementia (PDD) ANAVEX®2-73 MoA: S1R Activation is Upstream from other Therapeutic Targets

Neural cells suffer functional loss in neurological disorders which causes cellular stress

Pathologies include:

ü Aβ, Tau and ApoE fragmentation and dysfunction ü Proteinopathy

ü Microglia activation, migration, and dysregulation ü Apoptosis feedback loops that lead to neuronal degradation ü Autophagy dysfunction

ü Mitochondrial Dysfunction and Oxidative Stress that leads to further neuronal degradation

ü Neurodegeneration that spreads through a cascade of stress responses

S1R activates neuroprotective signals that help neurons return to homeostasis

S1R = Sigma-1 Receptor 8 ANAVEX®2-73 Establishes Human Proof-of-Concept and SIGMAR1 Target Occupancy 2D [18F]FTC-146-PET imaging of ANAVEX®2-73: Dose- ANAVEX®2-73 positive response in functional dependent ANAVEX®2-73 Target Engagement (ADCS-ADL*) outcome in Alzheimer’s disease patients correlate with SIGMAR1 mRNA levels

p-value of Mann–Whitney U test p=0.015 All n=20 patients in study. Slope of ADCS-ADL* from baseline to week 57 with available genomic data

0 mg /kg 1 mg/kg 10 mg/kg 30 mg/kg

100

80

1Receptor 60 -

40 Occupancy 20 PercentSigma 0 expression (TPM) SIGMAR1 RNA 0 5 10 15 20 25 30 mg/kg of ANAVEX2-73 Decrease (Negative) Increase (Positive)

Source: Reyes S et al, AAIC 2018; Hampel H et al. Alzheimer’s Dement. 2020;00:1–14; *Alzheimer's Disease Cooperative Study Activities of Daily Living 23-item scale (ADCS-ADL) 9 SIGMAR1 Activation has been Shown to Modulate Multiple Aspects of Neurodegenerative Processes

Sigma-1 receptor agonists ANAVEX®2-73 enhances Sigma-1 receptor agonists have been shown to restore autophagy and alleviates Tau have a neuroprotective effect neuronal functions in pathology in neurodegenerative in neurodegenerative disease neurodegenerative processes disease models models

10 What is Rett Syndrome? Devastating neuro-developmental disease in girls with both movement impairment and cognitive impairment

Rett Syndrome (RTT)

§ Non-inherited genetic postnatal disorder caused by mutations in the MECP2 gene Ø Occurs almost exclusively in girls Ø Leads to severe impairments, affecting nearly every aspect of the child’s life Ø Impairment includes ability to speak, walk, eat and even breathe easily Ø Hallmark of RTT is near constant repetitive hand movements while awake Ø Occurs worldwide in approximately one in every 10,000 to 15,000 live female births

Source: https://www.rettsyndrome.org/about-rett-syndrome 11 Phase 2 PART A: Improvement in All Key Domains

U.S. Rett Syndrome ANAVEX®2-73-RS-001 Trial (NCT03758924)

SUMMARY EFFICACY* • Phase 2, safety, tolerability, efficacy for 7 weeks, oral, liquid formulation, • Global severity RSBQ and CGI-I 5 mg daily (relatively low dose) RSBQ = Rett Syndrome Behavior Questionnaire • Part A: Intensive PK, n=6, Completed CGI-I = Clinical Global Impressions – Improvements • Part B: Randomized, double-blind, placebo-controlled, n=25, ongoing • Secondary: Behavior (ADAMS), Sleep (CSHQ), VAS (top caregiver • Females > 18 years, classic RTT w/MECP2 mutation concerns), Seizure diary • Evaluations at baseline (Week 0), Week 4 & Week 7 (End of Treatment) • Response Biomarker*: Glutamate, GABA; Genetic biomarker: • Good safety and tolerability: No serious adverse events, only three grade 1-2 adverse events DNA & RNA profiles

RSBQ Total RSBQ Hand Behaviors RSBQ Breathing Problems Sleep – CSHQ-Waking During the Night

Baseline We ek 7 Baseline We ek 7 Baseline We ek 7 Baseline We ek 7 0 0 0 0 1 0.5 10 2 2 1 20 3 1.5 4 p = 0.027 4 2 30

5 6 Waking During 2.5 - 40 6 3 the Night

RSBQ Total 8 7 CSHQ 3.5

50 - p = 0.042 8 4 RSBQ RSBQ Hand Behaviors 10 60 improves by p = 0.042 RSBQ Breathing Problems p = 0.042 9 Sleep 4.5 70 over 30% 10 12 5

*Preliminary evaluation of efficacy: two-tailed, nonparametric tests (conservative) 12 Precision Medicine

Biomarkers Increase Probability of Success 76%

55%

46%

28%

Phase II to Phase III Phase III to NDA/BLA Without Biomarkers With Patient Selection Biomarkers

Thomas DW et al. Clinical Development Success Rates 2006-2015. BIO Industry Analysis

13 In patients with RTT, MeCP2 deficiency leads to increased levels of Glutamate, Loss of synaptic in comparison to homeostasis can healthy controls1,2,3, impair nerve cells which results in (neurons) and excitatory-inhibitory their connections imbalance and further synaptic dysfunction

Glutamate as potential biomarker of microglia activation and synaptic dysfunction

1) Hamberger, A., et al., Elevated CSF glutamate in Rett syndrome. Neuropediatrics, 1992. 23(4): p. 212-3.;2) Lappalainen, R. and R.S. Riikonen, High levels of cerebrospinal fluid glutamate in Rett syndrome. Pediatr Neurol, 1996. 15(3): p. 213-6; 3) J.L. Neul at al., Metabolic signatures differentiate Rett syndrome from unaffected siblings. Frontiers in Integrative Neuroscience (2020) Vol14, Art 7, doi:10.3389/fnint.2020.00007 14 Phase 2 PART A: Reported Improvements Correlate with Biomarkers

U.S. Rett Syndrome ANAVEX®2-73-RS-001 Trial (NCT03758924)

Glutamate REPORT on PART A: INTENSIVE PK SUBCOHORT Baseline We ek 7 • Plasma levels of the biomarker Glutamate decreased significantly (Week 0 vs. Week 7; 2-tailed 0 Wilcoxon signed rank test, p = 0.046) 10 /L) /L) p = 0.046 • Levels of Glutamate at Week 7 directly correlated with CGI-I scores at Week 7 (2-tailed 20 mo Spearman’s rho = 0.837, p = 0.038) µ 30 • Greater decreases in Glutamate associated with greater improvement in these efficacy scores 40 • GABA changes demonstrated an inverse correlation of the magnitude of Glutamate changes (2- 50 Glutamate tailed Spearman’s rho = -0.829, p = 0.042) Glutamate ( 60 decreases by 70 over 40%

Significant Correlations: RSBQ & CGI-I Glutamate & CGI-I Glutamate & Hand Behaviors Glutamate & Sleep 40 5 8 5 7 35 4 4 6 5 30

I at Week 7 Week I at 3 - 4 3 25 I Week 7 7 I Week - CGI 2 3 CSHQ Total Visit 7 CGI

p = 0.003 - 20 2 2 1 p = 0.021 p = 0.005 1 p = 0.038 15

0 20 40 60 Sleep 1 0 RSBQ Total at Week 7 RSBQ Hand Behaviors Week 7 Improve- 10.00 20.00 30.00 40.00 -100 -50 0 50 10 ment Glutamate µmol/L Week 7 % Change in Glutamate 10.00 20.00 30.00 40.00 Glutamate µmol/L Week 7 15 ANAVEX®2-73 Phase 2 U.S. Rett Syndrome Study N=31* 7

RTT patient population ® ANAVEX 2-73 Primary and Secondary Endpoints # Active dose • PK, safety and tolerability of ANAVEX®2-73 • Diagnosis of • Behavioral symptoms confirmed RTT • Sleep function • Patients age >18 Randomization • Seizure activity • Entire DNA and RNA 3:2 Pre-specified Endpoints sequencing • Genetic variants SIGMAR1 (rs1800866), COMT ANAVEX®2-73-RS-001 STUDY ()* (rs113895332/rs61143203) with influence on treatment effect Placebo * Includes a 6 patient cohort undergoing a 7-week pharmacokinetic (PK) assessment with safety, tolerability, pharmacokinetic and efficacy evaluation of ANAVEX®2-73

# Oral liquid solution once daily; Dose restricted to maintain complete blinding 16 ANAVEX®2-73 Phase 2 Rett Syndrome AVATAR Study N=33* 7

RTT patient population ® ANAVEX 2-73 Primary and Secondary Endpoints # Active dose • Safety and tolerability of ANAVEX®2-73 • Diagnosis of • Behavioral symptoms confirmed RTT • Sleep function • Patients age >18 Randomization • Seizure activity • Entire DNA and RNA 3:2 Pre-specified Endpoints sequencing • Genetic variants SIGMAR1 (rs1800866), COMT ANAVEX®2-73-RS-001 STUDY (NCT0 (rs113895332/rs61143203) with influence on treatment effect Placebo * Includes a 3 patient cohort undergoing a 3-week pharmacokinetic (PK) assessment with safety, tolerability, pharmacokinetic and efficacy evaluation of ANAVEX®2-73

# Oral liquid solution once daily; Dose restricted to maintain complete blinding 17 ANAVEX®2-73-RS-003 Rett Syndrome EXCELLENCE Study N>69 12

RTT patient population ® ANAVEX 2-73 Primary and Secondary Endpoints # Active dose • Safety and tolerability of ANAVEX®2-73 • Diagnosis of • Behavioral symptoms confirmed RTT • Sleep function • Patients age 5-18 Randomization • Seizure activity • Entire DNA and RNA 2:1 Pre-specified Endpoints sequencing • Genetic variants SIGMAR1 (rs1800866), COMT ANAVEX®2-73-RS-001 STUDY (NCT037 (rs113895332/rs61143203) with influence on treatment effect Placebo

# Oral liquid solution once daily; Dose restricted to maintain complete blinding 18 Alzheimer’s Disease (AD) Alzheimer’s disease is a progressive, irreversible neurological disease and the most common cause of dementia

Alzheimer’s Disease (AD)

§ Alzheimer’s disease incidence highly correlates with age Ø AD prevalence in US:~5,700,000 Ø Estimated 50 million people live with dementia worldwide Ø Today, there are no commercially available therapies to address the underlying cause of Alzheimer’s Ø The current annual cost of dementia is estimated at $1 trillion, a figure set to double by 2030

Source: www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia/parkinson-s-disease-dementia 19 ANAVEX®2-73 Demonstrated Improved MMSE1 and ADCS-ADL2 Scores in Phase 2a AD Study through 148 Weeks SE) SE) ± ( ± 2 ( 1 ADL N=8 - N=8

N=13 N=13

p-value < 0.0008

Adjusted change in ADCS in change Adjusted p-value < 0.0001 Adjusted change in MMSE in change Adjusted

Source: Hampel et al. A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer’s disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study. Alzheimer’s Dement. 2020;00:1–14 1 Mini Mental State Examination (MMSE) 2 Alzheimer’s Disease Cooperative Study Group - Activities of Daily Living Inventory (ADCS-ADL) 20 ANAVEX®2-73 Phase 2b/3 Alzheimer's Disease and ATTENTION-AD OLE Study 48 N=450 … and Open Label Extension (OLE) 96 weeks Primary Endpoints Early AD patient population • ADAS-Cog ® ANAVEX 2-73 • ADCS-ADL High dose# • Confirmed amyloid • Safety and tolerability of pathophysiology ANAVEX®2-73 (CSF/amyloid PET) Key Secondary Endpoints • Patients aged 60 to • CDR-SB ® Randomization ANAVEX 2-73 • Structural and functional MRI 85 years Medium dose# 1:1:1 • Biomarkers: Abeta40/Abeta42, T-tau, • MMSE score 20-28 P-tau, NFL, YKL-40, neurogranin, • Entire DNA and RNA BACE1 sequencing Pre-specified Endpoints Placebo • Genetic variants SIGMAR1 (rs1800866), COMT (rs113895332/rs61143203) with influence on treatment effect

# Oral capsule once daily; Dose restricted to maintain complete blinding 21 Parkinson’s Disease Dementia (PDD) Up to 80 percent of those with Parkinson’s disease eventually experience Parkinson’s disease dementia

Parkinson’s Disease Dementia

§ Parkinson’s disease is a fairly common neurological disorder in older adults, estimated to affect nearly 2 percent of those older than age 65 Ø PD prevalence in US:~1,000,000 Ø The brain changes caused by Parkinson’s disease begin in a region that plays a key role in movement Ø Highly heterogeneous multisystem disorder Ø Etiology of cognitive impairment in PD has not yet been fully elucidated Ø As Parkinson’s brain changes gradually spread, they often begin to affect mental functions, including memory and the ability to pay attention, make sound judgments and plan the steps needed to complete a task

Source: Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, Ballard C. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017 Apr;13(4):217-231. doi: 10.1038/nrneurol.2017.27. Epub 2017 Mar 3. PMID: 28257128; PMCID: PMC5643027; www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia/parkinson-s-disease-dementia 22 ANAVEX®2-73 PoC Phase 2 PDD Study Design A Phase 2 trial to Assess the Safety, Tolerability and Efficacy of ANAVEX®2-73 (blarcamesine) Oral Capsules in the Treatment of Parkinson’s Disease Dementia 1:1:1 randomization

2-week baseline period 3-week up-titration period 11-week target dose treatment period Study data collected at Baseline, Week 8 and 14 Screening Baseline Week 3 Week 8 Week 14

ANAVEX®2-73 High Dose N=44 (10, 20, 30, then 50 mg QD) 2-week baseline ® N=132 including N=44 ANAVEX 2-73 Medium Dose actigraphy (10, 20, then 30 mg QD)

N=44 Placebo (QD) QD = once per day

• PDD Patient Population • Key Primary and Secondary • Pre-specified Endpoints ANAVEX®2-73-PDD- – Diagnosis of probable Parkinson’s disease Endpoints – Genetic variants SIGMAR1 001 is a Proof of Concept (PoC) dementia – Safety and tolerability (rs1800866), Phase 2, multicenter, – Diagnosis of idiopathic Parkinson’s disease – CDR Cognitive Domain of Attention – COMT(rs113895332/rs6114320 randomized, double- – Patients aged ≥ 50 years – Sleep function 3) with influence on treatment blind, placebo- effect controlled, parallel- – MoCA score 13-23 – MDS-UPDRS group, 3-arm, 14- – Actigraphy (24-hour monitoring) week study – Entire DNA and RNA sequencing

23 Key Cognitive Domains Key cognitive features addressed by ANAVEX®2-73 (blarcamesine)

The criteria from the National Institute on Aging and Alzheimer’s Association (NIA-AA) workgroup mention the following five Addressed in PoC cognitive domains when diagnosing MCI-AD: Phase 2 PDD Study (a) Episodic memory Episodic memory ✅ (b) Attention Choice reaction time ✅ Related CDR (c) Language system Word recognition ✅ domains (d) Visuospatial skills Picture recognition ✅

(e) Executive functions Numeric working memory ✅

Source: Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):270-9. doi: 10.1016/j.jalz.2011.03.008. Epub 2011 Apr 21. PMID: 21514249; PMCID: PMC3312027. 24 Significant Improvements in Episodic Memory with Increased Dose ANAVEX®2-73-PDD-001 Study: Dose-dependent, statistically significant improvement of Quality of Episodic Memory with ANAVEX®2-73 (blarcamesine)

Quality of Episodic Memory (counts) All participants Time: 14 weeks change from baseline

• A high score reflects ability to store, hold and retrieve information of an episodic nature (e.g., an event or name) 21.40

Direction of +42.22 • CDR system Quality -1.20 Improvement (counts) of Episodic Memory -20.82 highly correlated (70%) with ADAS-Cog (r = 0.7)1

1. Wesnes K, Edgar C, Andreasen N, Annas P, Basun H, Lannfelt L, et al. Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer’s disease. Acta Neurol Scand 2010; 122:270–7 All participants; ANAVEX2-73 = Active 30 mg, Active 50 mg vs Placebo J-T test based on actual maintenance dose: p = 0.003 25 Summary of Topline Results: Broad and Significant Effects with ANAVEX®2-73 (blarcamesine) in PDD Patients

• ANAVEX®2-73 (blarcamesine): a novel, oral, investigational sigma-1 receptor (Sig-1R / SIGMAR1) agonist with multimodal activity • Data confirm SIGMAR1 as gene “signature” biomarker of response to ANAVEX®2-73 (blarcamesine) confirming SIGMAR1 activation as mechanism of action • Broad and statistically significant improvements in CDR system Cognitive Domain of Attention assessed by Choice Reaction Time (p = 0.039) and Digital Vigilance (p = 0.008) and CDR system Episodic Memory (p = 0.047), representing complex cognitive tasks with impact on quality of life such as making a choice between similar objects and remembering daily personal experiences, which are mostly impaired in both PD and AD1 • Statistically significant dose-dependent (p = 0.003) improvement of CDR system Episodic Memory, which has been shown to be highly correlated (70%) with the Alzheimer’s Disease Assessment Scale–Cognitive score (ADAS-Cog; r = 0.7)2 • ANAVEX®2-73 (blarcamesine) does not impair sleep and has a positive effect on REM sleep behavior disorder • ANAVEX®2-73 (blarcamesine) was generally safe, well tolerated, and improved safety profile compared to dementia drugs associated with typical adverse effects • These results support continued development in PDD / PD as well as currently ongoing Phase 2 and Phase 2/3 clinical studies with ANAVEX®2-73 (blarcamesine) in Rett syndrome3 and Alzheimer’s disease4 • Data will be submitted to the U.S. Food and Drug Administration to seek regulatory guidance 1. Mahurin, R. K., & Pirozzolo, F. J. (1993). Application of Hick’s law of response speed in Alzheimer and Parkinson diseases. Perceptual and Motor Skills, 77(1), 107–113 2. Wesnes K, Edgar C, Andreasen N, Annas P, Basun H, Lannfelt L, et al. Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer’s disease. Acta Neurol Scand 2010; 122:270–7 3. ClinicalTrials.gov Identifiers: NCT03758924, NCT03941444, NCT04304482 4. ClinicalTrials.gov Identifiers: NCT03790709, NCT02756858 26 PRECISION MEDICINE IMPROVES CHANCE OF CLINICAL Anavex is pursuing Large Markets SUCCESS Testing for biomarkers demonstrated improved clinical response by Applying Precision Medicine to to ANAVEX®2-73 in Rett syndrome correlated with glutamate and for Alzheimer’s and Parkinson’s patients carrying wild-type (WT) Develop Treatments for both SIGMAR1 gene NOVEL CNS MECHANISM OF ACTION Global Aging CNS diseases ANAVEX®2-73, an orally available Sigma-1 receptor agonist, is upstream of neurodevelopment and neurodegeneration and (Alzheimer’s, Parkinson’s), as well has been shown to restore homeostasis as catastrophic Orphan COMPELLING INITIAL HUMAN DATA Genetically caused diseases, Rett ANAVEX®2-73 Phase 2 Parkinson’s disease dementia, ongoing Phase 2 in Rett syndrome and Phase 2a trial in Alzheimer’s with Syndrome with High Unmet Needs favorable safety and initial efficacy results through 148 weeks

WORLDWIDE COMMERCIAL RIGHTS AND STRONG IP $ 277B FOUNDATION We retain global commercial rights to all of our product Economic burden candidates and our lead product candidate, ANAVEX®2-73, including patent protection to 2030-2039 2018 Alzheimer’sAssociation

OVERARCHING MESSAGE SUFFICIENT CASH TO ACHIEVE KEY MILESTONES Sufficient cash for >24 months to achieve key milestones, A novel approach is needed to address the including non-dilutive cash from Australian government for totality of CNS diseases Alzheimer’s trial and from Rettsyndrome.org for Rett syndrome trial

27 Anavex Life Sciences Expertise Management Team Christopher U. Missling PhD - President & CEO

Walter E Kaufmann, MD - Chief Medical Officer

Stephan Toutain, MS, MBA – Chief Operating Officer

Emmanuel O Fadiran, RPh, PhD - SVP of Regulatory Affairs

Daniel Klamer, PhD - VP of Business Development & Scientific Strategy

Scientific Advisory Board Members

Jeffrey Cummings, MD Paul Aisen, MD

Corinne Lasmezas, PhD Norman Relkin, MD, PhD

Ottavio Arancio, MD, PhD Jacqueline French, MD

Andrew Cole, MD Dag Aarsland, MD, PhD

Daniel Weintraub, MD Tangui Maurice, PhD 28 Contact Us

Corporate Office Anavex®Life Sciences Corp. 51 West 52nd Street, 7th floor New York, NY 10019 1-844-689-3939

Shareholder & Media Relations [email protected] www.anavex.com NASDAQ: AVXL

29